# CAPSTONE-1

Source: https://onco.cc/trials/capstone-1/  
OnCo record `capstone-1` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The trial that added Hengrui's PD-L1 antibody adebrelimab to chemotherapy for small cell lung cancer, with one of the larger survival gains seen in that disease.

## Summary

462 patients, double blind. Median overall survival 15.3 versus 12.8 months (hazard ratio 0.72); two-year survival 31.3% versus 17.2%. NMPA approval March 2023. Together with ASTRUM-005 (serplulimab) it shows Chinese PD-(L)1 antibodies matching or exceeding the IMpower133 and CASPIAN benchmarks in a Chinese population.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-10
- Tags: china
- Registry id: NCT03711305
- Phase: 3
- Setting: First-line extensive-stage small cell lung cancer, China: adebrelimab or placebo plus carboplatin and etoposide
- Sponsor: Jiangsu Hengrui Pharmaceuticals
- Enrolled: 462
- Result: OS 15.3 vs 12.8 months, HR 0.72.
- Outcomes: Overall survival: Adebrelimab + EC 15.3 months vs Placebo + EC 12.8 months, HR 0.72

## Sources

- ClinicalTrials.gov NCT03711305: https://clinicaltrials.gov/study/NCT03711305
- Lancet Oncol 2022: https://doi.org/10.1016/S1470-2045(22)00224-8

## Connected records

- trials: [ASTRUM-005](https://onco.cc/trials/astrum-005/), [CASPIAN](https://onco.cc/trials/caspian/), [IMpower133](https://onco.cc/trials/impower133/)
- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Etoposide](https://onco.cc/drugs/etoposide/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- institutions: [Jilin Cancer Hospital](https://onco.cc/institutions/jilin-cancer-hospital/)
- people: [Ying Cheng](https://onco.cc/people/cheng-ying/)
- key papers: [Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](https://onco.cc/key-papers/paper-capstone-1-lancet-oncol-2022/)

---
JSON: https://onco.cc/api/v1/entities/capstone-1.json